Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
Relieved of ‘high-risk’ marker, New Horizon Health aims to break even next year
Encouraged by its fast-growing revenue last year, the cancer screening device maker believes its losses may end in 2023 Key Takeaways: New Horizon Health is expected to attract more investors…
6606.HK
Lab testing chain Adicon joins IPO rush as Covid cash dwindles
One of China’s biggest independent laboratory operators is trying to jump on the Hong Kong IPO bandwagon before its Covid testing revenues tumble Key takeaways: Adicon’s Covid test services powered…
Zai Lab sees profits on the horizon as commercialization accelerates
The innovative drug maker’s loss narrowed last year, as it forecast potential profitability as soon as 2025 on fast-growing revenues Key Takeaways: Zai Lab is set to reach several product…
9688.HK
ZLAB.US
Testing times for diagnostics firm UGenix as Covid demand drops
The medical technology company is looking to list in Hong Kong after a windfall from Covid testing, but its other screening services are not yet lucrative Key Takeaways: Covid tests…
CanSino looks for next growth shot in ‘life after Covid’
The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades Key Takeaways: CanSino logged sizable asset impairments for its…
6185.HK
688185.SHG
Yonghe suffers Covid fallout, but eyes return to growth with China reopening
The nation’s leading hair transplant provider was forced to close nearly all of its clinics at different times last year due to the country’s strict Covid controls Key Takeaways: Yonghe…
2279.HK
